h1

h2

h3

h4

h5
h6

001     1026919
005     20260129055619.0
024 7 _ |a 1574-7891
|2 ISSN
024 7 _ |a 1878-0261
|2 ISSN
024 7 _ |a SCOPUS:2-s2.0-105021830661
|2 SCOPUS
024 7 _ |a WOS:001611310400001
|2 WOS
024 7 _ |a 10.1002/1878-0261.70148
|2 doi
024 7 _ |a 10.18154/RWTH-2026-01055
|2 datacite_doi
037 _ _ |a RWTH-2026-01055
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Schmitz, Jutta
|b 0
245 _ _ |a Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107
|h online
260 _ _ |a Hoboken, NJ
|b John Wiley & Sons, Inc.
|c 2025
336 7 _ |0 0
|2 EndNote
|a Journal Article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
500 _ _ |a First published: 11 November 2025
588 _ _ |a Dataset connected to CrossRef, Journals: publications.rwth-aachen.de
591 _ _ |a Germany
591 _ _ |a Netherlands
700 1 _ |a Bartkowiak, Anna L.
|b 1
700 1 _ |0 P:(DE-82)IDM06249
|a Rose, Michael
|b 2
|u rwth
700 1 _ |a Kolks, Nora
|b 3
700 1 _ |0 0000-0002-8355-5524
|a Petzsch, Patrick
|b 4
700 1 _ |a Solanki, Vandana
|b 5
700 1 _ |a Stoffel, Anne
|b 6
700 1 _ |a Faßbender, Bianca
|b 7
700 1 _ |a Lepping, Leandra
|b 8
700 1 _ |a Volkamer, Julka
|b 9
700 1 _ |a Köhrer, Karl
|b 10
700 1 _ |a Seifert, Marc
|b 11
700 1 _ |a Mahmoudi, Tokameh
|b 12
700 1 _ |a Zuiverloon, Tahlita C. M.
|b 13
700 1 _ |0 0000-0001-6929-8691
|a Niegisch, Günter
|b 14
|e Corresponding author
700 1 _ |0 0000-0002-6044-1671
|a Hoffmann, Michèle J.
|b 15
|e Corresponding author
773 _ _ |0 PERI:(DE-600)2322586-5
|a 10.1002/1878-0261.70148
|t Molecular oncology
|x 1878-0261
|y 2025
856 4 _ |u https://publications.rwth-aachen.de/record/1026919/files/1026919.pdf
|y OpenAccess
909 C O |o oai:publications.rwth-aachen.de:1026919
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |0 I:(DE-588b)36225-6
|6 P:(DE-82)IDM06249
|a RWTH Aachen
|b 2
|k RWTH
914 1 _ |y 2025
915 1 _ |0 StatID:(DE-HGF)0031
|2 StatID
|a Peer reviewed article
|x 0
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-07
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOL ONCOL : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-08-08T17:04:26Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-08-08T17:04:26Z
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-07
|w ger
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-01-07
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Open peer review
|d 2024-08-08T17:04:26Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-01-07
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOL ONCOL : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
920 1 _ |0 I:(DE-82)528001-2_20140620
|k 528001-2 ; 922910
|l Institut und Lehrstuhl für Pathologie
|x 0
980 _ _ |a I:(DE-82)528001-2_20140620
980 _ _ |a UNRESTRICTED
980 _ _ |a VDB
980 _ _ |a journal
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21